All Stories

  1. High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study

    Article • Expert Review of Gastroenterology & Hepatology, June 2019, Taylor & Francis

    Professor Kadry Elsaeed, Dr Heba Omar, Mohamed Shaker , Yehia El Shazly, Mohamed El Kassas

  2. DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV

    Article • Expert Review of Gastroenterology & Hepatology, May 2019, Taylor & Francis

    Dr Heba Omar, Shereen Abdel Alem, Aisha Elsharkawy , Dr Walid Kamal Ibrahim

  3. Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort

    Article • Expert Review of Gastroenterology & Hepatology, November 2018, Taylor & Francis

    Professor Kadry Elsaeed, Dr Heba Omar

  4. Professor of Internal Medicine, Consultant Hepatologist

    Article • Alimentary Pharmacology & Therapeutics, November 2017, Wiley

    Mohamed El Kassas, Dr Heba Omar, Professor Monkez M Yousif

  5. Statins Added to Chronic Hepatitis C Treatment: Is it Beneficial?

    Article • Journal of Hepatology and Gastrointestinal disorders, January 2016, OMICS Publishing Group

    Dr Heba Omar

  6. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma

    Article • World Journal of Hepatology, January 2014, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Heba Omar

  7. Tissue Biomarkers in the Early Detection of Hepatocellular Carcinoma among Egyptian Patients with Chronic Hepatitis C: A Possible Genetic Profile

    Article • British Journal of Medicine and Medical Research, January 2013, Sciencedomain International

    Dr Heba Omar